Canaan leaps into UK biotech by co-leading $14M Series A for immuno-oncology upstart Grey Wolf

Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn?t work across all cancers. To remedy this, UK-based biotech upstart Grey Wolf Therapeutics is working on a fresh approach that does not directly target the immune system, but instead alters tumor cells by illuminating and priming them for immune system annihilation ? a strategy that could work in conjunction with existing immunotherapies.

Andera Partners and Canaan have shown their faith in the concept by leading an approximately $14 million series A round for the company.

Peter Joyce

Founded by former Vertex executive?Peter Joyce and ex-chief of?Spinifex Pharmaceuticals?Tom McCarthy, Grey Wolf is developing?small molecule